Hormonal
GLP-1 receptor agonists improve cardiovascular outcomes by reducing major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with type 2 diabetes and established cardiovascular disease.
If you have type 2 diabetes and existing heart disease, certain GLP-1 medications (like liraglutide, semaglutide, or dulaglutide) can significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit is independent of weight loss and is a key reason these drugs are recommended for high-risk patients.
Long-acting GLP-1 RAs were found to be superior to placebo in reduction of the primary MACE endpoint in the following trials: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (liraglutide), SUSTAIN 6 (semaglutide QW), REWIND (dulaglutide)...
Why this rating
Supported by multiple large-scale RCTs (LEADER, SUSTAIN 6, REWIND) and meta-analyses.
Source
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01615-5
More from this paper
- Treatment with GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produces substantial body weight loss (exceeding 15%) and improves glucose control, leading to type 2 diabetes prevention and possible disease remission.Strong
- GLP-1 receptor agonists improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing liver fat content, liver stiffness, and liver enzymes (ALT, AST).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →